Drug Trial Radar · NCT06643780
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 9, 2024
Primary completion
Apr 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Prince of Wales Hospital, Shatin, Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese University of Hong Kong
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Conditions
- Sarcopenia in Elderly
Interventions
DenosumabDrug
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
Zolendronic AcidDrug
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-metre walkTime frame: From enrollment to the end of treatment at 52 weeks
- 5-time chair stand testTime frame: From enrollment to the end of treatment at 8 weeks
- Appendicular skeletal muscle mass (ASM)Time frame: From enrollment to the end of treatment at 52 weeks
- Handgrip strengthTime frame: From enrollment to the end of treatment at 52 weeks
- Quadriceps muscle strengthTime frame: From enrollment to the end of treatment at 52 weeks
- Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
- Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
- Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
- Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
- Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Chinese University of Hong Kong
Hong Kong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.